文献速递主动脉疾病

开窗支架治疗近肾腹主动脉瘤的早中期疗效

Early and Mid-term Efficacy of Fenestrated Endograft in the Treatment of Juxta-Renal Aortic Aneurysms.
PubMed 文献 · Ann Vasc Surg · 2019-10-31

本研究前瞻性收集2008至2017年连续接受开窗支架(FEVAR)治疗的近肾腹主动脉瘤(J-AAA)病例,报告其早中期结局。在181例FB-EVAR中,66例(36%)为J-AAA。技术成功率达99%,30天死亡率为1.5%,5年免于再干预率为88%,5年生存率为67%,无动脉瘤相关死亡。FEVAR治疗J-AAA安全有效,解剖适合的高危患者可考虑作为一线治疗,术前COPD与远期生存率降低独立相关。

要点

  • FEVAR治疗近肾腹主动脉瘤技术成功率高,早中期结果安全有效。
  • 5年免于再干预率88%,5年生存率67%,无动脉瘤相关死亡。
  • 术前COPD是远期死亡的唯一独立预测因素。

核心结论

  • FEVAR治疗近肾腹主动脉瘤在早中期随访中安全有效,解剖适合的高危患者可考虑作为一线治疗。
  • 术前存在COPD的患者远期生存率降低。

研究设计与样本

  • 前瞻性收集2008年至2017年连续接受FEVAR治疗的近肾腹主动脉瘤病例。
  • 共181例接受FB-EVAR,其中66例(36%)为近肾腹主动脉瘤。

主要发现

  • 技术成功65例(99%),唯一失败为III型内漏需肾动脉补救。
  • 30天死亡1例(1.5%),为唯一死亡病例。
  • 平均随访46±32个月,瘤囊缩小42例(64%),稳定22例(33%)。
  • 5年免于再干预率88%,5年生存率67%,无动脉瘤相关死亡。
  • 多因素分析显示COPD是死亡的唯一独立预测因素(P=0.021;OR=5.3;95%CI 1.3-21.9)。

关键数值与推荐

  • 技术成功定义为65例(99%)成功,无目标内脏血管丢失。
  • 肾功能恶化7例(10%),其中4例30天内恢复基线,1例需血透并死亡(1.5%)。
  • 随访期间肾功能恶化5例(8%),无晚期肾动脉闭塞或I-III型内漏。
  • 5年免于再干预率88%,5年生存率67%。

临床怎么用

  • 对于解剖适合的高危近肾腹主动脉瘤患者,FEVAR可作为一线治疗选择。
  • 术前应评估COPD,因其与远期生存率降低独立相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of this study was to report early and mid-term outcomes of fenestrated endografting (FEVAR) for juxtarenal aneurysm (J-AAAs). METHODS: Between 2008 and 2017, all consecutive J-AAAs treated by FEVAR were prospectively collected. Early endpoints were technical success, renal function worsening, and 30-day mortality. Follow-up endpoints were survival, freedom from reinterventions (FFRs), target visceral vessels (TVVs) patency, J-AAAs shrinkage, and renal function worsening. RESULTS: Among 181 cases who underwent FB-EVAR, 66 (36%) were J-AAAs. Endograft with 1, 2, 3, and 4 fenestrations were planned in 2 (3%), 22 (33%), 27 (41%) and 15 (23%) cases, respectively. Overall, 236 TVVs were treated by fenestrations and scallops. Technical success was achieved in 65 (99%) cases. The only failure occurred for a type III endoleak requiring renal artery relining. No TVVs were lost. Renal function worsening occurred in 7 (10%) cases: 4 returned to baseline within 30-day, 1 required hemodialysis and died within 30 days (1.5%). This was the only case of 30-day mortality. The mean follow-up was 46 ± 32 months. Aneurysm sac shrinkage or stability was observed in 42 (64%) and 22 (33%) cases, respectively. Two patients (3%) with persistent type II endoleak had sac enlargement and required reinterventions. Freedom from reinterventions at 5 years was 88%. An asymptomatic celiac trunk occlusion (accommodated by a scallop) occurred at 24 months in a case with a severe preoperative stenosis. No late renal arteries occlusions or type I-III endoleaks occurred. Overall, renal function worsening was reported in 5 (8%) patients during follow-up. Survival at 5 years was 67%, with no j-AAA-related mortality. COPD was the only independent predictor for mortality at the multivariate analysis (P: 0.021; OR: 5.3; 95% CI, 1.3-21.9). CONCLUSIONS: FEVAR for J-AAAs is safe and effective at early and mid-term follow-up. According to these results, it could be proposed as the first-line treatment in high-risk patients if anatomically fit. Long-term survival is reduced in the presence of preoperative COPD.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Gallitto E, Faggioli G, Giordano J, et al. Early and Mid-term Efficacy of Fenestrated Endograft in the Treatment of Juxta-Renal Aortic Aneurysms. Ann Vasc Surg. 2019. PMID: 31678126. doi:10.1016/j.avsg.2019.10.077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。